These data show that a staggered JAKi maintenance therapy-type approach may alter T cell activation and exhaustion characteristics, improve longer-term CAR T cell anti-leukemia activity, and prevent CRLF2+ ALL relapse following TSLPRCART immunotherapy. The gene discussed is CRLF2; the disease is leukemia.